NZ629432A - Heterocyclyl compounds as mek inhibitors - Google Patents

Heterocyclyl compounds as mek inhibitors

Info

Publication number
NZ629432A
NZ629432A NZ629432A NZ62943213A NZ629432A NZ 629432 A NZ629432 A NZ 629432A NZ 629432 A NZ629432 A NZ 629432A NZ 62943213 A NZ62943213 A NZ 62943213A NZ 629432 A NZ629432 A NZ 629432A
Authority
NZ
New Zealand
Prior art keywords
compounds
disclosed
iodophenyl
pyrimidine
fluoro
Prior art date
Application number
NZ629432A
Other languages
English (en)
Inventor
Bhavesh Dave
Rakesh Kumar Banerjee
Samiron Phukan
Abhijit Datta Khoje
Rajkumar Hangarge
Jitendra Sambhaji Jadhav
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ629432(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of NZ629432A publication Critical patent/NZ629432A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
NZ629432A 2012-03-14 2013-03-11 Heterocyclyl compounds as mek inhibitors NZ629432A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14
PCT/IB2013/051908 WO2013136249A1 (en) 2012-03-14 2013-03-11 Heterocyclyl compounds as mek inhibitors

Publications (1)

Publication Number Publication Date
NZ629432A true NZ629432A (en) 2017-01-27

Family

ID=47997632

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ629432A NZ629432A (en) 2012-03-14 2013-03-11 Heterocyclyl compounds as mek inhibitors
NZ629442A NZ629442A (en) 2012-03-14 2013-03-11 Heterocyclyl compounds as mek inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ629442A NZ629442A (en) 2012-03-14 2013-03-11 Heterocyclyl compounds as mek inhibitors

Country Status (35)

Country Link
US (5) US9573944B2 (index.php)
EP (2) EP2834236B1 (index.php)
JP (3) JP6093384B2 (index.php)
KR (4) KR102241111B1 (index.php)
CN (4) CN104203947A (index.php)
AP (2) AP3859A (index.php)
AU (4) AU2013234009B2 (index.php)
BR (1) BR112014022713B1 (index.php)
CA (2) CA2865167C (index.php)
CL (2) CL2014002412A1 (index.php)
CO (2) CO7170131A2 (index.php)
CR (2) CR20140464A (index.php)
CU (2) CU24335B1 (index.php)
DK (2) DK2834237T3 (index.php)
DO (2) DOP2014000204A (index.php)
EA (2) EA028232B1 (index.php)
ES (2) ES2741896T3 (index.php)
GE (2) GEP201706671B (index.php)
GT (2) GT201400195A (index.php)
IL (2) IL234560A (index.php)
IN (2) IN2014MN01755A (index.php)
MA (2) MA37405A1 (index.php)
MX (3) MX366426B (index.php)
MY (2) MY175950A (index.php)
NI (2) NI201400108A (index.php)
NZ (2) NZ629432A (index.php)
PE (2) PE20141973A1 (index.php)
PH (2) PH12014502040B1 (index.php)
PL (1) PL2834237T3 (index.php)
SG (2) SG11201405006PA (index.php)
TN (2) TN2014000357A1 (index.php)
TR (1) TR201811976T4 (index.php)
UA (2) UA114907C2 (index.php)
WO (2) WO2013136249A1 (index.php)
ZA (1) ZA201406186B (index.php)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
KR102241111B1 (ko) 2012-03-14 2021-04-15 루핀 리미티드 Ｍｅｋ 억제제로서 헤테로사이클릴 화합물
HUE052195T2 (hu) 2012-06-13 2021-04-28 Incyte Holdings Corp Szubsztituált triciklusos vegyületek mint FGFR inhibitorok
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN109776525B (zh) 2013-04-19 2022-01-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
CA2927635C (en) * 2013-10-25 2021-07-20 Shanghai Hengrui Pharmaceutical Co., Ltd. Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) * 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN113004278B (zh) 2015-02-20 2023-07-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10898487B2 (en) 2016-12-22 2021-01-26 Boehringer Ingelheim International Gmbh Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
UA126173C2 (uk) * 2017-12-21 2022-08-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Бензиламінозаміщені піридопіримідинони та похідні як інгібітори sos1
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
MD3788047T2 (ro) 2018-05-04 2025-03-31 Incyte Corp Forme solide ale unui inhibitor al FGFR și procedee de preparare a acestuia
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020296914A1 (en) 2019-06-19 2021-12-23 Boehringer Ingelheim International Gmbh Anticancer combination therapy
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7724549B2 (ja) * 2019-07-30 2025-08-18 エドヴィンス エービー 脳卒中の処置のためのｍｅｋ阻害剤
EP3797899A1 (de) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4157836B1 (en) * 2020-06-02 2025-10-29 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
JP2024514127A (ja) 2021-04-09 2024-03-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗がん剤療法
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3215081A1 (en) * 2021-04-16 2022-10-20 Alfredo C. Castro Mek inhibitors and uses thereof
JP2024521788A (ja) 2021-05-27 2024-06-04 ミラティ セラピューティクス， インコーポレイテッド 併用療法
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US20250313553A1 (en) 2021-12-01 2025-10-09 Boehringer Ingelheim Int'l GmbH Corp. Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
JP2024543982A (ja) 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がんの処置のための縮環２－アミノ－３－シアノチオフェン及び誘導体
CR20240233A (es) 2021-12-01 2024-07-17 Univ Vanderbilt Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer
US20250145608A1 (en) 2021-12-01 2025-05-08 Boehringer Ingelheim Int'l GmbH Corp. Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
US20250129096A1 (en) 2021-12-01 2025-04-24 Boehringer Ingelheim Int'l GmbH Corp. Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
AR132802A1 (es) 2023-05-30 2025-07-30 Boehringer Ingelheim Int 2-amino-3-cianotiofenos con anillos espirocíclicos y derivados para el tratamiento del cáncer
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
RS51044B (sr) * 2002-01-22 2010-10-31 Warner-Lambert Company Llc. 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-oni
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
ZA200604580B (en) 2003-11-19 2009-08-26 Array Biopharma Inc Heterocyclic inhibitors of Mek and methods of use thereof
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
RS52670B (sr) * 2004-06-11 2013-06-28 Japan Tobacco Inc. Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido(2,3-d)pirimidina i slična jedinjenja za lečenje kancera
AU2009344690A1 (en) 2009-04-21 2011-10-27 Novartis Ag Heterocyclic compounds as MEK inhibitors
KR102241111B1 (ko) * 2012-03-14 2021-04-15 루핀 리미티드 Ｍｅｋ 억제제로서 헤테로사이클릴 화합물

Also Published As

Publication number Publication date
BR112014022713B1 (pt) 2021-09-08
EA029768B1 (ru) 2018-05-31
US20150133424A1 (en) 2015-05-14
AU2017200493B2 (en) 2018-03-29
US20160331753A1 (en) 2016-11-17
CO7170131A2 (es) 2015-01-28
JP2015509975A (ja) 2015-04-02
ZA201406186B (en) 2016-06-29
AU2018202568A1 (en) 2018-05-10
AP3834A (en) 2016-09-30
EP2834236B1 (en) 2019-05-22
PE20141974A1 (es) 2014-12-12
CU20140109A7 (es) 2014-11-27
JP6630771B2 (ja) 2020-01-15
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
UA114907C2 (uk) 2017-08-28
CN108383836A (zh) 2018-08-10
MY174188A (en) 2020-03-12
CN107698585A (zh) 2018-02-16
CU24272B1 (es) 2017-08-08
AU2017200493A1 (en) 2017-02-16
PL2834237T3 (pl) 2018-11-30
IN2014MN01755A (index.php) 2015-07-03
UA114906C2 (uk) 2017-08-28
AU2013234014B2 (en) 2017-02-02
MA37400A1 (fr) 2016-05-31
ES2741896T3 (es) 2020-02-12
US9555035B2 (en) 2017-01-31
CR20140463A (es) 2014-11-28
JP6093384B2 (ja) 2017-03-08
GT201400195A (es) 2017-11-09
CO7160029A2 (es) 2015-01-15
EA201491672A1 (ru) 2014-12-30
PE20141973A1 (es) 2014-12-12
JP6431770B2 (ja) 2018-11-28
PH12014502040A1 (en) 2014-11-24
KR20190100472A (ko) 2019-08-28
US9969731B2 (en) 2018-05-15
DK2834237T3 (en) 2018-08-27
NI201400107A (es) 2014-11-26
HK1202538A1 (en) 2015-10-02
HK1206020A1 (en) 2015-12-31
AU2013234014A1 (en) 2014-09-25
DOP2014000203A (es) 2015-02-15
ES2684517T3 (es) 2018-10-03
EP2834236A1 (en) 2015-02-11
AP2014008009A0 (en) 2014-10-31
PH12014502041A1 (en) 2014-11-24
CU24335B1 (es) 2018-04-03
MX366426B (es) 2019-07-08
MX355526B (es) 2018-04-20
CN104271577A (zh) 2015-01-07
CA2865164A1 (en) 2013-09-19
KR20140138911A (ko) 2014-12-04
US20150299186A1 (en) 2015-10-22
TR201811976T4 (tr) 2018-09-21
JP2018115215A (ja) 2018-07-26
DOP2014000204A (es) 2015-02-15
WO2013136249A1 (en) 2013-09-19
US9573944B2 (en) 2017-02-21
EP2834237B1 (en) 2018-06-06
TN2014000357A1 (en) 2015-12-21
CA2865164C (en) 2021-06-08
NI201400108A (es) 2014-11-28
KR20140138910A (ko) 2014-12-04
CL2014002411A1 (es) 2015-04-06
AP3859A (en) 2016-10-31
AP2014008008A0 (en) 2014-10-31
SG11201405007QA (en) 2014-10-30
MX2014010928A (es) 2015-04-10
MX2014010925A (es) 2015-04-10
AU2018202568B2 (en) 2019-05-09
AU2013234009B2 (en) 2016-10-27
IL234559A (en) 2017-06-29
US9428499B2 (en) 2016-08-30
EA201491671A1 (ru) 2014-12-30
CN104203947A (zh) 2014-12-10
DK2834236T3 (da) 2019-08-26
EP2834237A1 (en) 2015-02-11
IN2014MN01754A (index.php) 2015-07-03
BR112014022713A2 (index.php) 2017-06-20
KR20190073597A (ko) 2019-06-26
PH12014502041B1 (en) 2014-11-24
MX355474B (es) 2018-04-16
US20170101408A1 (en) 2017-04-13
EA028232B1 (ru) 2017-10-31
GEP201706774B (en) 2017-11-27
KR102241111B1 (ko) 2021-04-15
GEP201706671B (en) 2017-05-25
US9827247B2 (en) 2017-11-28
CA2865167A1 (en) 2013-09-19
KR102240101B1 (ko) 2021-04-14
WO2013136254A1 (en) 2013-09-19
NZ629442A (en) 2016-12-23
PH12014502040B1 (en) 2014-11-24
AU2013234009A1 (en) 2014-09-25
CA2865167C (en) 2019-08-06
CL2014002412A1 (es) 2015-03-06
CN108383836B (zh) 2021-11-12
US20170112840A1 (en) 2017-04-27
MA37405A1 (fr) 2016-03-31
SG11201405006PA (en) 2014-10-30
MA37400B1 (fr) 2019-11-29
CU20140110A7 (es) 2014-11-27
IL234560A (en) 2017-06-29
JP2015514056A (ja) 2015-05-18
GT201400196A (es) 2017-09-28
CR20140464A (es) 2014-11-28

Similar Documents

Publication Publication Date Title
NZ629432A (en) Heterocyclyl compounds as mek inhibitors
MY158193A (en) Morpholino pyrimidines and their use in therapy
NZ702571A (en) 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
NZ630721A (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
PH12018500437A1 (en) Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof
MX2015002511A (es) Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos.
CA2918938C (en) Substituted aminopyrimidine compounds and methods of use
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
UA115320C2 (uk) Інгібітори кінази
MY186126A (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
HK1202541A1 (en) 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
MX2014006026A (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2013008296A (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
WO2013004995A8 (en) Pyrimidinone compounds and their use
MX358172B (es) Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
MX340574B (es) Imidazo pirazinas.
MX2013002384A (es) Compuestos quinazolina y metodos para utilizarlos.
MY180039A (en) N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
MX341577B (es) Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero.
WO2014062838A3 (en) Pkm2 modulators and methods for their use
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 MAR 2020 BY WRAYS

Effective date: 20170509

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2021 BY WRAYS PTY LTD

Effective date: 20191211

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2022 BY WRAYS PTY LTD

Effective date: 20201215

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2023 BY WRAYS PTY LTD

Effective date: 20220308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2024 BY IRG

Effective date: 20230214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250206